We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
Read MoreHide Full Article
Key Takeaways
TNDM launched early U.S. access for t:slim X2 pump compatible with Abbott's FreeStyle Libre 3 Plus sensor.
Abbott's Libre 3 Plus sends glucose data every minute to TNDM's t:slim mobile app.
TNDM plans to integrate Abbott's future sensors for broader diabetes management solutions.
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the United States. The company has initiated an early access program in the country and plans to scale its availability in the second half of 2025.
TNDM Stock’s Likely Trend Following the News
Since the announcement, TNDM’s shares edged up 1.6% to $20.55 last Friday.
Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. The flagship t:slim X2’s integration with the CGM partners’ sensors validates the company’s effort to strengthen its market expansion ability. Accordingly, we expect the latest launch of Control-IQ+ technology to motivate market sentiment toward the TNDM stock in the upcoming days.
Tandem Diabetes currently has a market capitalization of $1.35 billion. It has an estimated earnings per share (EPS) growth rate of 28.3% in 2025 compared with the industry’s 13.8% rise. Per the Zacks Consensus Estimate, the company’s revenues for 2025 are expected to increase 10.6%.
More on t:slim X2’s Compatibility With FreeStyle Libre 3 Plus
The t:slim X2 insulin pump, powered by Control-IQ+ technology, is the latest generation of Tandem Diabetes’ advanced hybrid closed-loop algorithm, which adjusts insulin every five minutes based on predicted glucose values. It is the only system with the unique AutoBolus feature that calculates and delivers a correction bolus to help with missed meal boluses.
Control-IQ+ is easy to start, use, and personalize, and when working with the FreeStyle Libre 3 Plus sensor, it extends benefits to even more people with diabetes. Meanwhile, Abbott’s FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend.
Industry Prospects Favor TNDM
Per a report by Grand View Research, the global insulin delivery device market was valued at $16.43 billion in 2023 and is expected to witness a CAGR of 7.9% by 2027.
Image Source: Zacks Investment Research
The surge in market growth is primarily driven by the rising global prevalence of diabetes, which has created a greater need for advanced and user-friendly solutions for diabetes management. Technological advancements play a crucial role in the market growth, with devices becoming more effective, less invasive and personalized to meet patients' individual needs.
Another Development by TNDM
Earlier this month, Tandem Diabetes entered into an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.
Additionally, in March, the company commercially launched its Control-IQ+ technology, the latest generation of its advanced hybrid closed-loop algorithm in the United States.
TNDM Stock Price Performance
In the past year, TNDM shares have lost 49.4% compared with the industry’s decline of 14.8%.
TNDM’s Zacks Rank and Key Picks
Tandem Diabetes currently carries a Zacks Rank #3 (Hold).
Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry’s 9.9% rise. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry’s 3.3% decline in the past year.
Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry’s -10.1%. Shares of the company have surged 129.7% compared with the industry’s 35.9% gain. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.8%.
Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 3.8%. Shares of the company have rallied 25.9% against the industry’s 14.4% decline. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
Key Takeaways
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the United States. The company has initiated an early access program in the country and plans to scale its availability in the second half of 2025.
TNDM Stock’s Likely Trend Following the News
Since the announcement, TNDM’s shares edged up 1.6% to $20.55 last Friday.
Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. The flagship t:slim X2’s integration with the CGM partners’ sensors validates the company’s effort to strengthen its market expansion ability. Accordingly, we expect the latest launch of Control-IQ+ technology to motivate market sentiment toward the TNDM stock in the upcoming days.
Tandem Diabetes currently has a market capitalization of $1.35 billion. It has an estimated earnings per share (EPS) growth rate of 28.3% in 2025 compared with the industry’s 13.8% rise. Per the Zacks Consensus Estimate, the company’s revenues for 2025 are expected to increase 10.6%.
More on t:slim X2’s Compatibility With FreeStyle Libre 3 Plus
The t:slim X2 insulin pump, powered by Control-IQ+ technology, is the latest generation of Tandem Diabetes’ advanced hybrid closed-loop algorithm, which adjusts insulin every five minutes based on predicted glucose values. It is the only system with the unique AutoBolus feature that calculates and delivers a correction bolus to help with missed meal boluses.
Control-IQ+ is easy to start, use, and personalize, and when working with the FreeStyle Libre 3 Plus sensor, it extends benefits to even more people with diabetes. Meanwhile, Abbott’s FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend.
Industry Prospects Favor TNDM
Per a report by Grand View Research, the global insulin delivery device market was valued at $16.43 billion in 2023 and is expected to witness a CAGR of 7.9% by 2027.
Image Source: Zacks Investment Research
The surge in market growth is primarily driven by the rising global prevalence of diabetes, which has created a greater need for advanced and user-friendly solutions for diabetes management. Technological advancements play a crucial role in the market growth, with devices becoming more effective, less invasive and personalized to meet patients' individual needs.
Another Development by TNDM
Earlier this month, Tandem Diabetes entered into an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.
Additionally, in March, the company commercially launched its Control-IQ+ technology, the latest generation of its advanced hybrid closed-loop algorithm in the United States.
TNDM Stock Price Performance
In the past year, TNDM shares have lost 49.4% compared with the industry’s decline of 14.8%.
TNDM’s Zacks Rank and Key Picks
Tandem Diabetes currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , Hims & Hers Health (HIMS - Free Report) and Cencora (COR - Free Report) .
Align Technology has an estimated long-term earnings growth rate of 11.2% compared with the industry’s 9.9% rise. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 3.4%. Its shares have lost 27.7% compared with the industry’s 3.3% decline in the past year.
ALGN sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry’s -10.1%. Shares of the company have surged 129.7% compared with the industry’s 35.9% gain. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.8%.
Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 3.8%. Shares of the company have rallied 25.9% against the industry’s 14.4% decline. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%.